Coronary disease & ACSSecondary analysis
Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention
- Secondary analysis of the TWILIGHT randomised trial
- landmark analysis at 3 months
Authors' conclusion
In the TWILIGHT trial, dyspnea-related ticagrelor discontinuation occurred in almost 1 in 10 patients and tended to occur earlier rather than late after PCI.
Study context
- Population
- Patients after percutaneous coronary intervention (PCI) in the TWILIGHT trial
- Comparison
- Ticagrelor monotherapy vs ticagrelor plus aspirin
- Primary endpoint
- Incidence, predictors and outcomes of dyspnea-related ticagrelor discontinuation
Primary result
As reported in the abstract
Dyspnea-related ticagrelor discontinuation (incidence)
Incidence at 3 months after PCI
6.4%
Incidence at 15 months after PCI
9.1%
Further findings
Subsequent ischemic events (all-cause death, MI or stroke) among those discontinuing for dyspnea after randomization
P = 0.566
- Subsequent ischemic events (all-cause death, MI or stroke) among those discontinuing for dyspnea after randomization: n = 179 discontinued for dyspnea after randomization
Original publication
Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention. JACC Cardiovasc Interv. Published 23 October 2023. doi:10.1016/j.jcin.2023.08.019
Summarised from the published abstract; every number is checked against it